Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.

Liver international : official journal of the International Association for the Study of the Liver - 1 May 2008

Kennedy Patrick T F, Phillips Natalie, Chandrasekhar Jaya, Jacobs Ruth, Jacobs Michael, Dusheiko Geoffrey

Abstract excerpt

BACKGROUND: Current oral therapy for hepatitis B virus (HBV) is limited by the presence of resistance leading to resumption of higher levels of HBV replication. Therefore, there is a need for a better definition of the potential role and limitations of lamivudine or similar therapies, used alone....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B virus

Share to Lamivudine

Share to Longitudinal Studies

Share to Reverse Transcriptase Inhibitors

Share to Treatment Outcome

Share to Virus Replication

Source

Identifiers

PMID: 18433396
DOI: 10.1111/j.1478-3231.2008.01717.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18433396-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping.PMID 18433396Read ↗

Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Semantic proximity Read ↗

HBV mutations associated with lamivudine therapy.Semantic proximity Read ↗

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine.Semantic proximity Read ↗

Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factorsSemantic proximity Read ↗

Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.Semantic proximity Read ↗

Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.Semantic proximity Read ↗

Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.Semantic proximity Read ↗

Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.Semantic proximity Read ↗

Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients.Semantic proximity Read ↗

Hepatitis B virus subtypes and lamivudine resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.